PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30415182-1 2019 Calcineurin-inhibitor induced pain syndrome (CIPS) is a condition characterized by lower extremity pain in patients receiving tacrolimus or cyclosporine therapy following organ transplantation. Cyclosporine 140-152 calcineurin binding protein 1 Homo sapiens 0-21 30547226-10 2019 In support of this, the calcineurin inhibitor, cyclosporin A, prevented the Ca2+-induced decrease in cell surface CFTR. Cyclosporine 47-60 calcineurin binding protein 1 Homo sapiens 24-45 30577261-10 2018 CONCLUSIONS: Using advanced modeling methodologies of longitudinal data we identified that the factors associated with acute cellular rejection during the first year after the transplant are related to the therapeutic levels of the calcineurin inhibitor (cyclosporin) during the first 6 months of follow-up and the age of the receptor. Cyclosporine 255-266 calcineurin binding protein 1 Homo sapiens 232-253 30376962-0 2018 Are Adverse Events Induced by the Acute Administration of Calcineurin Inhibitor Cyclosporine A Behaviorally Conditioned in Healthy Male Volunteers? Cyclosporine 80-94 calcineurin binding protein 1 Homo sapiens 58-79 27643869-2 2017 We previously showed that rTM increased levels of antiapoptotic protein Mcl-1 and protected endothelial cells from calcineurin inhibitor cyclosporine A (CsA)-induced apoptosis. Cyclosporine 153-156 calcineurin binding protein 1 Homo sapiens 115-136 28724911-3 2017 Interestingly, the calcineurin inhibitor (CNI) cyclosporine A (CsA), an immunosuppressant used to prevent allograft rejection, can also increase the risk of RCC in transplant patients. Cyclosporine 47-61 calcineurin binding protein 1 Homo sapiens 19-40 28724911-3 2017 Interestingly, the calcineurin inhibitor (CNI) cyclosporine A (CsA), an immunosuppressant used to prevent allograft rejection, can also increase the risk of RCC in transplant patients. Cyclosporine 63-66 calcineurin binding protein 1 Homo sapiens 19-40 28583569-15 2017 CONCLUSIONS: A high-dose MZ regimen including calcineurin inhibitor (CsA or Tac), Bas, Rit, and steroids was effective and safe in reducing the frequency of CMV-related events in ABO-i LKT. Cyclosporine 69-72 calcineurin binding protein 1 Homo sapiens 46-67 27982677-2 2017 The long-term outcomes of solid organ transplant recipients have improved considerably since the introduction of the first calcineurin inhibitor (CNI) - cyclosporine. Cyclosporine 153-165 calcineurin binding protein 1 Homo sapiens 123-144 27306529-0 2016 Calcineurin Inhibitor Nephrotoxicity Through the Lens of Longitudinal Histology: Comparison of Cyclosporine and Tacrolimus Eras. Cyclosporine 95-107 calcineurin binding protein 1 Homo sapiens 0-21 27742194-4 2016 The proinflammatory effects of FGF23 are inhibited by an isoform-specific FGFR4 blocking antibody and by cyclosporine, a calcineurin inhibitor. Cyclosporine 105-117 calcineurin binding protein 1 Homo sapiens 121-142 26954314-4 2016 Cyclosporine, a potent calcineurin inhibitor that acts selectively on T-cells, revolutionized the world of immunosuppression upon its discovery in 1970. Cyclosporine 0-12 calcineurin binding protein 1 Homo sapiens 23-44 26160968-2 2015 Because sirolimus (SIR) and calcineurin inhibitor-either cyclosporine (CsA) or tacrolimus-have become more common as graft-versus-host disease (GVHD) prophylaxis, we are witnessing a higher frequency of this complication. Cyclosporine 57-69 calcineurin binding protein 1 Homo sapiens 28-49 26496921-6 2016 Furthermore, we show that inhibition of the interaction with calcineurin inhibitor, cyclosporin A (CsA), leads to the retention of ATOH8 to the cytoplasm, suggesting that the interaction renders nuclear localization of ATOH8 which may be critical to control its activity as transcription factor. Cyclosporine 84-97 calcineurin binding protein 1 Homo sapiens 61-82 26496921-6 2016 Furthermore, we show that inhibition of the interaction with calcineurin inhibitor, cyclosporin A (CsA), leads to the retention of ATOH8 to the cytoplasm, suggesting that the interaction renders nuclear localization of ATOH8 which may be critical to control its activity as transcription factor. Cyclosporine 99-102 calcineurin binding protein 1 Homo sapiens 61-82 26463642-6 2016 A calcineurin inhibitor, cyclosporine has been used as an immunosuppressive agent in corneal transplantation since the 1980"s. Cyclosporine 25-37 calcineurin binding protein 1 Homo sapiens 2-23 26160968-2 2015 Because sirolimus (SIR) and calcineurin inhibitor-either cyclosporine (CsA) or tacrolimus-have become more common as graft-versus-host disease (GVHD) prophylaxis, we are witnessing a higher frequency of this complication. Cyclosporine 71-74 calcineurin binding protein 1 Homo sapiens 28-49 25661468-7 2015 Here, we describe a very unusual neuropsychiatric side effect of tacrolimus and its resolution with another calcineurin inhibitor, cyclosporine, in an adolescent renal transplant recipient. Cyclosporine 131-143 calcineurin binding protein 1 Homo sapiens 108-129 25883698-6 2015 Calcineurin inhibitor, which includes cyclosporine, pimecrolimus and tacrolimus, impairs calcineurin-induced up-regulation of IL-2 expression, resulting in increased susceptibility to invasive fungal diseases. Cyclosporine 38-50 calcineurin binding protein 1 Homo sapiens 0-21 25591474-1 2015 Cyclosporine, a calcineurin inhibitor, is successfully used as an immunosuppressant in transplant medicine. Cyclosporine 0-12 calcineurin binding protein 1 Homo sapiens 16-37 25003316-3 2014 In the present study we investigated calcineurin dependent or independent cytotoxic effects of CsA, a calcineurin inhibitor, in cervical cancerous SiHa cells. Cyclosporine 95-98 calcineurin binding protein 1 Homo sapiens 102-123 25645789-2 2015 The objective of this study is to compare the incidence of development of obesity after HT, according to the calcineurin inhibitor (CNI) used (cyclosporine [CsA] vs tacrolimus [Tac]). Cyclosporine 143-155 calcineurin binding protein 1 Homo sapiens 109-130 25132585-1 2014 Cyclosporine, a calcineurin inhibitor, is a potent immunosuppressive agent that acts chiefly through the inactivation of T-lymphocytes. Cyclosporine 0-12 calcineurin binding protein 1 Homo sapiens 16-37 23677660-1 2012 Calcineurin inhibitor encephalopathy (CIE) is a rare condition occurring in patients who are undergoing treatment with drugs from the calcineurin inhibitor (CI) family of immunosuppressants, either cyclosporine (CsA) or tacrolimus (TAC, FK506). Cyclosporine 198-210 calcineurin binding protein 1 Homo sapiens 0-21 24932812-0 2014 Clinical outcome in heart transplant recipients receiving everolimus in combination with dosage reduction of the calcineurin inhibitor cyclosporine A or tacrolimus. Cyclosporine 135-149 calcineurin binding protein 1 Homo sapiens 113-134 23743217-1 2013 The discovery of the first calcineurin inhibitor (CNI), cyclosporine, represents a watershed event in the history of immunosuppression, as it was the first drug shown to reversibly inhibit T-lymphocyte function, therefore allowing for one of the major breakthroughs in modern medicine, that of organ transplantation. Cyclosporine 56-68 calcineurin binding protein 1 Homo sapiens 27-48 24925208-5 2014 Therefore, we developed and evaluated the application, reliability and validity of a novel adverse effects scoring system in renal transplant recipients receiving calcineurin inhibitor (cyclosporine or tacrolimus) and mycophenolic acid based immunosuppressive therapy. Cyclosporine 186-198 calcineurin binding protein 1 Homo sapiens 163-184 22580614-4 2013 We demonstrate that cyclosporine A (CsA, an immunophilin/calcineurin inhibitor) induces cell death with some apoptotic features but also accompanied by the appearance of numerous cytoplasmic vacuoles, immunostained for endoplasmic reticulum (ER) and autophagy markers. Cyclosporine 36-39 calcineurin binding protein 1 Homo sapiens 57-78 23677660-1 2012 Calcineurin inhibitor encephalopathy (CIE) is a rare condition occurring in patients who are undergoing treatment with drugs from the calcineurin inhibitor (CI) family of immunosuppressants, either cyclosporine (CsA) or tacrolimus (TAC, FK506). Cyclosporine 198-210 calcineurin binding protein 1 Homo sapiens 134-155 23677660-1 2012 Calcineurin inhibitor encephalopathy (CIE) is a rare condition occurring in patients who are undergoing treatment with drugs from the calcineurin inhibitor (CI) family of immunosuppressants, either cyclosporine (CsA) or tacrolimus (TAC, FK506). Cyclosporine 198-210 calcineurin binding protein 1 Homo sapiens 38-40 23677660-1 2012 Calcineurin inhibitor encephalopathy (CIE) is a rare condition occurring in patients who are undergoing treatment with drugs from the calcineurin inhibitor (CI) family of immunosuppressants, either cyclosporine (CsA) or tacrolimus (TAC, FK506). Cyclosporine 212-215 calcineurin binding protein 1 Homo sapiens 0-21 23677660-1 2012 Calcineurin inhibitor encephalopathy (CIE) is a rare condition occurring in patients who are undergoing treatment with drugs from the calcineurin inhibitor (CI) family of immunosuppressants, either cyclosporine (CsA) or tacrolimus (TAC, FK506). Cyclosporine 212-215 calcineurin binding protein 1 Homo sapiens 38-40 22476221-6 2012 Both protease inhibitors can modify the levels of drugs metabolized by the CYP3A/4 pathway, and in posttransplant patients, the protease inhibitors increase the levels of cyclosporine and tacrolimus, with the magnitude of the drug-drug interactions varying with protease inhibitor and type of calcineurin inhibitor (CNI). Cyclosporine 171-183 calcineurin binding protein 1 Homo sapiens 293-314 23018254-1 2012 BACKGROUND: Calcineurin inhibitor (cyclosporine, CsA) and mTOR inhibitors (sirolimus, SRL) - immunosuppressants used to prevent allograft rejection after renal transplantation - have a narrow therapeutic index and show considerable inter-individual pharmacokinetic differences. Cyclosporine 35-47 calcineurin binding protein 1 Homo sapiens 12-33 22852277-1 2012 Immunosuppressive therapy designed to prevent kidney graft rejection usually consists of a triple-drug combination including a corticosteroid, a calcineurin inhibitor (ciclosporin or tacrolimus) and a drug that inhibits cell proliferation (azathioprine or mycophenolate mofetil). Cyclosporine 168-179 calcineurin binding protein 1 Homo sapiens 145-166 22729026-1 2012 PURPOSE OF REVIEW: The purpose of the review is to review the pathophysiology, available data, and our current recommendations for calcineurin inhibitor (cyclosporine and tacrolimus) treatment in antihistamine refractory chronic idiopathic urticaria (CIU) patients. Cyclosporine 154-166 calcineurin binding protein 1 Homo sapiens 131-152 22476221-6 2012 Both protease inhibitors can modify the levels of drugs metabolized by the CYP3A/4 pathway, and in posttransplant patients, the protease inhibitors increase the levels of cyclosporine and tacrolimus, with the magnitude of the drug-drug interactions varying with protease inhibitor and type of calcineurin inhibitor (CNI). Cyclosporine 171-183 calcineurin binding protein 1 Homo sapiens 316-319 21262237-1 2011 AIMS: Cyclosporin A, a calcineurin inhibitor, produces neurotoxicity with relatively high frequency in organ-transplanted patients. Cyclosporine 6-19 calcineurin binding protein 1 Homo sapiens 23-44 22320241-1 2012 Early conversion to a calcineurin-inhibitor (CNI)-free maintenance immunosuppression with sirolimus (SRL), mycophenolate mofetil (MMF) and steroids was associated with an improved 1-year renal function as compared with a cyclosporine (CsA)-based regimen (SMART core-study). Cyclosporine 221-233 calcineurin binding protein 1 Homo sapiens 22-43 22320241-1 2012 Early conversion to a calcineurin-inhibitor (CNI)-free maintenance immunosuppression with sirolimus (SRL), mycophenolate mofetil (MMF) and steroids was associated with an improved 1-year renal function as compared with a cyclosporine (CsA)-based regimen (SMART core-study). Cyclosporine 235-238 calcineurin binding protein 1 Homo sapiens 22-43 22151386-2 2012 Cyclosporin A, a calcineurin inhibitor, is used as a standard immunosuppressant and clearly increases the skin cancer risk. Cyclosporine 0-13 calcineurin binding protein 1 Homo sapiens 17-38 22118788-4 2011 After the first month, maintenance therapy mostly consists in the association of several immunosuppressants, mainly corticosteroids, an antimetabolic agent (azathioprine or mycophenolate mofetil) and a calcineurin inhibitor (cyclosporine or tacrolimus). Cyclosporine 225-237 calcineurin binding protein 1 Homo sapiens 202-223 21738288-1 2011 The observation that cyclosporine inhibits HCV replication in vitro has led some programs to use cyclosporine as the calcineurin inhibitor (CNI) of choice after orthotopic liver transplantation (OLT). Cyclosporine 21-33 calcineurin binding protein 1 Homo sapiens 117-138 21738288-1 2011 The observation that cyclosporine inhibits HCV replication in vitro has led some programs to use cyclosporine as the calcineurin inhibitor (CNI) of choice after orthotopic liver transplantation (OLT). Cyclosporine 97-109 calcineurin binding protein 1 Homo sapiens 117-138 21693287-1 2011 The calcineurin inhibitor cyclosporine (CSA) displays nephrotoxic side effects. Cyclosporine 26-38 calcineurin binding protein 1 Homo sapiens 4-25 22419339-3 2012 Currently, more than 90% of all liver transplant recipients are treated with the calcineurin inhibitor cyclosporine or tacrolimus. Cyclosporine 103-115 calcineurin binding protein 1 Homo sapiens 81-102 22419339-18 2012 This ongoing trial studies total withdrawal of immunosuppression in patients who receive a calcineurin inhibitor (cyclosporine or tacrolimus) or mycophenolate mofetil as the only immunosuppressive agent. Cyclosporine 114-126 calcineurin binding protein 1 Homo sapiens 91-112 21895616-4 2012 METHODS: The patient"s immunosuppression was switched from the calcineurin inhibitor ciclosporin to the mTOR inhibitor everolimus. Cyclosporine 85-96 calcineurin binding protein 1 Homo sapiens 63-84 22310597-5 2012 Because the abnormally elevated C(t) was falsely measured by the ACMIA method, we restarted tacrolimus However, the calcineurin inhibitor was subsequently converted to cyclosporine at day 21 after renal transplantation. Cyclosporine 168-180 calcineurin binding protein 1 Homo sapiens 116-137 21028918-7 2010 Nearly all regimens include a calcineurin inhibitor (either ciclosporin [cyclosporine] or tacrolimus). Cyclosporine 60-71 calcineurin binding protein 1 Homo sapiens 30-51 19930311-3 2009 Calcineurin inhibitor such as ciclosporin A inhibits T-cell activation by interfering with the cytosolic protein cyclophilin (immunophilin). Cyclosporine 30-43 calcineurin binding protein 1 Homo sapiens 0-21 20726688-5 2010 Amongst the last is the calcineurin inhibitor (CNI) (cyclosporine A (CsA) and tacrolimus)-related nephrotoxicity. Cyclosporine 53-67 calcineurin binding protein 1 Homo sapiens 24-45 20571464-1 2010 Chronic calcineurin inhibitor (CNI)-induced nephrotoxicity is associated with prolonged use of cyclosporine and tacrolimus and has been observed after all types of transplantation, as well as during treatment of autoimmune disease. Cyclosporine 95-107 calcineurin binding protein 1 Homo sapiens 8-29 20565370-4 2010 Induction therapy was given to 94 patients (82.4%), and maintenance immunosuppression consisted of calcineurin inhibitor (cyclosporin microemulsion or tacrolimus), together with mycophenolate mofetil and prednisone. Cyclosporine 122-133 calcineurin binding protein 1 Homo sapiens 99-120 19691367-2 2009 Maintenance therapy typically consists of a triple-drug regimen including corticosteroids, a calcineurin inhibitor (ciclosporin or tacrolimus) and either a purine synthesis antagonist (mycophenolate mofetil or azathioprine) or a mammalian target of rapamycin inhibitor (sirolimus or everolimus). Cyclosporine 116-127 calcineurin binding protein 1 Homo sapiens 93-114 16960140-7 2006 The current findings could be relevant for the osteoporosis seen in patients given the calcineurin inhibitor cyclosporine to prevent transplant rejection, although the results need to be reconciled with aspects of the clinical picture. Cyclosporine 109-121 calcineurin binding protein 1 Homo sapiens 87-108 18293408-3 2008 NFATs are activated by calcium-mobilizing agents in astrocytes, and this activation is blocked by the calcineurin inhibitor cyclosporine A. Cyclosporine 124-138 calcineurin binding protein 1 Homo sapiens 102-123 19356075-1 2008 The calcineurin inhibitor cyclosporine is removed from lymphocytes by the drug efflux transporter P-glycoprotein (P-gp) encoded by the ABCB1 gene for which several single nucleotide polymorphisms (SNPs) have been identified. Cyclosporine 26-38 calcineurin binding protein 1 Homo sapiens 4-25 16997418-1 2006 Aerosolized cyclosporine was the first calcineurin inhibitor to be developed for inhaled administration. Cyclosporine 12-24 calcineurin binding protein 1 Homo sapiens 39-60 16829796-4 2006 Glucocorticoids and the calcineurin inhibitor cyclosporine induce endothelial dysfunction, and although tacrolimus may not have the same disruptive effects on endothelial function as cyclosporine, its endothelial activity is still being established. Cyclosporine 46-58 calcineurin binding protein 1 Homo sapiens 24-45 16307158-8 2005 Moreover, in favour of non-endotoxin-mediated white cell activation, the calcineurin inhibitor, cyclosporin-A, which did not alter endotoxin-induced TNF-alpha production, decreased TNF-alpha produced by unstimulated cultured cells in patients to values not significantly greater than those in controls. Cyclosporine 96-109 calcineurin binding protein 1 Homo sapiens 73-94 16467444-1 2006 The calcineurin inhibitor cyclosporine (CsA) induces a fibrogenic response that may lead to scarring of the renal allograft. Cyclosporine 40-43 calcineurin binding protein 1 Homo sapiens 4-25 16467444-1 2006 The calcineurin inhibitor cyclosporine (CsA) induces a fibrogenic response that may lead to scarring of the renal allograft. Cyclosporine 26-38 calcineurin binding protein 1 Homo sapiens 4-25 12887261-15 2003 In the current immunosuppressive regimens, a calcineurin inhibitor, either tacrolimus or cyclosporin, is the essential basic standard immunosuppressant. Cyclosporine 89-100 calcineurin binding protein 1 Homo sapiens 45-66 16182764-2 2005 Standard primary immunosuppressive therapy after orthotopic liver transplantation (OLT) is based on a calcineurin-inhibitor (CNI): cyclosporine or tacrolimus. Cyclosporine 131-143 calcineurin binding protein 1 Homo sapiens 102-123 16182764-2 2005 Standard primary immunosuppressive therapy after orthotopic liver transplantation (OLT) is based on a calcineurin-inhibitor (CNI): cyclosporine or tacrolimus. Cyclosporine 131-143 calcineurin binding protein 1 Homo sapiens 125-128 15773954-6 2005 An individualized approach to choice of calcineurin inhibitor, by which cyclosporine or tacrolimus are selected based on the patient"s particular risk profile, may thus help to reduce the toll of cardiovascular mortality among renal transplant recipients in the future. Cyclosporine 72-84 calcineurin binding protein 1 Homo sapiens 40-61 15837449-3 2005 Evidence from large-scale analyses of registry databases has shown that the calcineurin inhibitor, tacrolimus, is associated with approximately a 50% increase in the risk of NODM compared to the microemulsion formulation of cyclosporine (CsA); but to date, little robust evidence is available from clinical trials. Cyclosporine 224-236 calcineurin binding protein 1 Homo sapiens 76-97 15496263-3 2004 For most patients, optimal current immunosuppression in the first year after transplantation consists of combination therapy with a calcineurin inhibitor (eg, cyclosporine or tacrolimus), corticosteroids, and an antimetabolite agent (eg, azathioprine or mycophenolate mofetil). Cyclosporine 159-171 calcineurin binding protein 1 Homo sapiens 132-153 15341497-9 2004 The calcineurin inhibitor ciclosporin (cyclosporine) not only induces these same adverse effects as corticosteroids but is also nephrotoxic. Cyclosporine 26-37 calcineurin binding protein 1 Homo sapiens 4-25 15341497-9 2004 The calcineurin inhibitor ciclosporin (cyclosporine) not only induces these same adverse effects as corticosteroids but is also nephrotoxic. Cyclosporine 39-51 calcineurin binding protein 1 Homo sapiens 4-25 15619640-1 2004 Calcineurin-inhibitor induced pain syndrome (CIPS) is a newly described entity with a characteristic feature of sudden onset of severe lower limb pain, and high levels of cyclosporine or tacrolimus may be involved in the pathogenesis. Cyclosporine 171-183 calcineurin binding protein 1 Homo sapiens 0-21 12742481-1 2003 Calcineurin inhibitor drugs (CNI), primarily cyclosporine then tacrolimus, have been the centerpieces of maintenance immunosuppression for kidney transplantation since their introduction in the 1980s. Cyclosporine 45-57 calcineurin binding protein 1 Homo sapiens 0-21 15192777-3 2004 The calcineurin inhibitor (cyclosporine A = 9, tacrolimus = 3) was reduced by 50 %, and rapamycin added to reach a target level of 8 - 12 ng/dL. Cyclosporine 27-41 calcineurin binding protein 1 Homo sapiens 4-25 15093807-10 2004 In addition, there is evidence from studies in renal transplant recipients that everolimus plus reduced exposure cyclosporine is effective and well tolerated-with the regimen having a reduced potential for CNI-related nephrotoxicity and for other CNI-related cardiovascular side effects. Cyclosporine 113-125 calcineurin binding protein 1 Homo sapiens 247-250 15001192-1 2004 BACKGROUND: Calcineurin inhibitor drugs (cyclosporine and tacrolimus) given to renal transplant recipients to prevent rejection are associated with an increased incidence of hypertension. Cyclosporine 41-53 calcineurin binding protein 1 Homo sapiens 12-33 15782552-5 2004 Cyclosporine A, a potent calcineurin inhibitor, has been used as a second line therapy. Cyclosporine 0-14 calcineurin binding protein 1 Homo sapiens 25-46 10612271-3 1999 Calcineurin inhibitor-induced acute renal failure may occur as early as a few weeks or months after initiation of cyclosporin therapy. Cyclosporine 114-125 calcineurin binding protein 1 Homo sapiens 0-21 12499886-9 2002 CONCLUSION: Collectively, these findings support the utility of combined treatment with captopril and CsA in the multitherapeutic management of organ transplant and, possibly, a strategy to decrease the dose of the calcineurin inhibitor in kidney-transplant recipients. Cyclosporine 102-105 calcineurin binding protein 1 Homo sapiens 215-236 12008048-3 2002 Similar changes were observed if cells were treated with the calcineurin inhibitor Cyclosporin-A. Cyclosporine 83-96 calcineurin binding protein 1 Homo sapiens 61-82 11726837-2 2001 Hyperuricemia and gout have been associated with the use of the calcineurin inhibitor, cyclosporine. Cyclosporine 87-99 calcineurin binding protein 1 Homo sapiens 64-85 11558493-2 2001 We did a randomised controlled trial of mycophenolate mofetil monotherapy in liver transplant patients who developed renal failure associated with calcineurin-inhibitor (ciclosporin or tacrolimus) immunosuppressive therapy. Cyclosporine 170-181 calcineurin binding protein 1 Homo sapiens 147-168 11263551-8 2001 The Calcineurin-inhibitor Induced Pain Syndrome (CIPS) is a rare but severe side effect of cyclosporine or tacrolimus and is accurately diagnosed by its typical presentation, magnetic resonance imaging and bone scans. Cyclosporine 91-103 calcineurin binding protein 1 Homo sapiens 4-25 8702699-6 1996 Cyclosporin-A, another calcineurin inhibitor, also prevented the augmented cAMP response. Cyclosporine 0-13 calcineurin binding protein 1 Homo sapiens 23-44 32625210-5 2020 The aim of this project is to investigate the effects of (oral) donor preconditioning with a calcineurin inhibitor (Cyclosporine) vs. an inhibitor of mammalian target for Rapamycin (Everolimus) compared to the conventional administration of steroid in the setting of donation after brain death in porcine renal transplantation. Cyclosporine 116-128 calcineurin binding protein 1 Homo sapiens 93-114 34483914-1 2021 Remdesivir, a prodrug targeting RNA-dependent-RNA-polymerase, and cyclosporine, a calcineurin inhibitor, individually exerted inhibitory activity against human coronavirus OC43 (HCoV-OC43) in HCT-8 and MRC-5 cells at EC50 values of 96 +- 34 ~ 85 +- 23 nM and 2,920 +- 364 ~ 4,419 +- 490 nM, respectively. Cyclosporine 66-78 calcineurin binding protein 1 Homo sapiens 82-103 32505466-0 2020 Cyclosporine as a preferred calcineurin inhibitor in renal allograft recipients with COVID-19 infection. Cyclosporine 0-12 calcineurin binding protein 1 Homo sapiens 28-49 32692785-7 2020 We found that TBB (a casein kinase II inhibitor), AR and LiCl (GSK-3 inhibitors), cyclosporin A (calcineurin inhibitor), and Saracatinib (Fyn kinase inhibitor) caused robust inhibition of OA-induced monomeric and oligomeric p-tau in both N2a and CTX culture. Cyclosporine 82-95 calcineurin binding protein 1 Homo sapiens 97-118 34426105-2 2021 Ciclosporin, a calcineurin inhibitor, is characterized by beneficial antiviral and immunomodulatory effects. Cyclosporine 0-11 calcineurin binding protein 1 Homo sapiens 15-36 35280715-7 2022 We initiated a combination therapy with prednisolone and cyclosporine as a calcineurin inhibitor. Cyclosporine 57-69 calcineurin binding protein 1 Homo sapiens 75-96 31325587-6 2019 Specifically, compared with cyclosporine/MMF as GVHD prophylaxis, the odds ratio (OR) for calcineurin inhibitor/methotrexate was .8 and for cyclosporine/prednisone .6. Cyclosporine 28-40 calcineurin binding protein 1 Homo sapiens 90-111